High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: Facts and opinions

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2042-2047

  Ferreri, Andrés J M ^a   Crocchiolo, Roberto ^a,b   Assanelli, Andrea ^a,b   Govi, Silvia ^a   Reni, Michele ^a  

^a Medical Oncology Unit   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Autologous transplant; CNS; Lymphoma; Methotrexate; Neurotoxicity; Thiotepa

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; NITROSOUREA; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG FATALITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER FAILURE; MEDICAL RESEARCH; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; RISK ASSESSMENT; SEPSIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 57049182361     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802381238     Document Type: Review

References (21)

1. Ferreri, A. J., Foppoli, M., Martelli, M., Pangalis, G., Frezzato, M. Cabras, G. et al. (2008) Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients with primary CNS lymphoma (PCNSL). Ann Oncol, 19
2. Ferreri, A. J., Foppoli, M., Martelli, M., Pangalis, G., Frezzato, M. Cabras, G. et al. (2008) Randomized phase 2 trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients with primary CNS lymphoma (PCNSL). Haematologica
3. Ferreri, A. J., Dell'Oro, S., Foppoli, M., Bernardi, M., Brandes, A. A. Tosoni, A. et al. (2006) MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology, 66, pp. 1435-1438.
4. Khalfallah, S., Stamatoullas, A., Fruchart, C., Proust, F., Delangre, T. and Tilly, H. (1996) Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant, 18, pp. 1021-1023.
5. Soussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V. Azar, N. et al. (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol, 19, pp. 742-749.
6. Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S. Witz, F. et al. (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moëlle Osseuse-Therapie Cellulaire. J Clin Oncol, 26, pp. 2512-2518.
7. Brevet, M., Garidi, R., Gruson, B., Royer, B., Vaida, I. and Damaj, G. (2005) First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol, 75, pp. 288-292.
8. Colombat, P., Lemevel, A., Bertrand, P., Delwail, V., Rachieru, P. Brion, A. et al. (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group. Bone Marrow Transplant, 38, pp. 417-420.
9. Illerhaus, G., Marks, R., Ihorst, G., Guttenberger, R., Ostertag, C. Derigs, G. et al. (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol, 24, pp. 3865-3870.
10. Illerhaus, G., Muller, F., Feuerhake, F., Schafer, A. O., Ostertag, C. and Finke, J. (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica, 93, pp. 147-148.
11. Montemurro, M., Kiefer, T., Schuler, F., Al-Ali, H. K., Wolf, H. H. Herbst, R. et al. (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol, 18, pp. 665-671.
12. Abrey, L. E., Moskowitz, C. H., Mason, W. P., Crump, M., Stewart, D. Forsyth, P. et al. (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis. J Clin Oncol, 21, pp. 4151-4156.
13. Cheng, T., Forsyth, P., Chaudhry, A., Morris, D., Gluck, S. Russell, J. A. et al. (2003) High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant, 31, pp. 679-685.
14. Fischer, L., Thiel, E., Klasen, H. A., Birkmann, J., Jahnke, K. Martus, P. et al. (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol, 17, pp. 1141-1145.
15. Voloschin, A. D., Betensky, R., Wen, P. Y., Hochberg, F. and Batchelor, T. (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol, 86, pp. 211-215.
16. Reni, M., Zaja, F., Mason, W., Perry, J., Mazza, E. Spina, M. et al. (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer, 96, pp. 864-867.
17. Plotkin, S. R., Betensky, R. A., Hochberg, F. H., Grossman, S. A., Lesser, G. J. Nabors, L. B. et al. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res, 10, pp. 5643-5646.
18. Arellano-Rodrigo, E., Lopez-Guillermo, A., Bessell, E. M., Nomdedeu, B., Montserrat, E. and Graus, F. (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol, 70, pp. 219-224.
19. Tyson, R. M., Siegal, T., Doolittle, N. D., Lacy, C., Kraemer, D. F. and Neutwelt, E. A. (2003) Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma, 44, pp. 627-633.
20. Reni, M., Mazza, E., Foppoli, M. and Ferreri, A. J. (2007) Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate. Cancer Lett, 258, pp. 165-170.
21. Wiebe, V. J., Smith, B. R., DeGregorio, M. W. and Rappeport, J. M. (1992) Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol, 13, pp. 241-270.